We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IMRN:NASDAQImmuron Limited analysis

Data as of Sep 30, 2026 - not real-time

Latest price
$1.19
Risk: high
9/10High risk

Summary

The moving-average structure behind Immuron Limited is bullish at $1.19, with short-term averages leading the long-term ones. Over a rolling month the price has gained 10.2%. Relative strength is 46.5 — neutral — and the MACD signal is bearish. Recent trading has carved out support near $1.06 and resistance around $1.99.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 227.4% above today's level. Revenue is growing at 7.2% on a -47.7% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 162.4%, a beta of 0.66 and a maximum drawdown of 70.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.

Top market events

  • Shares of Immuron Limited IMRN are surging Friday morning following news that the Australian biopharmaceutical company...
  • Benzinga.com2monImmuron Earnings & ForecastsImmuron IMRN last issued guidance on July 16, 2026 for fiscal year 2026....
  • MELBOURNE, Australia, Sept. 04, 2026 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN is pleased to announce...

Market outlook

Short term

< 1 year

Neutral

Model confidence2/102 out of 10

Key factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 1.00
  • MACD momentum is negative

Medium term

1–3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 1.00
  • Analyst targets imply +227.4% versus the current price

Long term

> 3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • Negative profit margin of -47.7%
  • Analyst targets imply +227.4% versus the current price
  • Negative return on equity of -38.3%

Key metrics

Financial health

Revenue Growth7.20%
Profit Margin-47.71%
P/E Ratio-119.0
ROE-38.27%
ROA-19.14%
Debt/Equity1.70
P/B Ratio1.2
Op. Cash Flow$-3259720
Free Cash Flow$-2070447
Industry P/E30.5

Technical analysis

TrendBullish
RSI46.5
Support$1.06
Resistance$1.99
MA 20$1.32
MA 50$1.20
MA 200$1.00
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Target Price$3.90
Upside/Downside227.37%
GradeFair
TypeBlend

Risk assessment

Beta0.66
Volatility162.37%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.